Uncategorized

The rare disease space is awaiting two FDA verdicts in February, one for a genetic disease and another for a non-malignant tumor.

 Tazbaz was director of the FDA’s Digital Health Center of Excellence for two years, leading key policies on artificial intelligence and software as a medical device.

Vulnerabilities in certain Contec and Epsimed patient monitors can allow people to gain access and potentially manipulate the devices, the FDA warned.

The diabetes tech firm began trading this week and was valued at $966.2 million as of Thursday.

A spokesperson for the Greater New York Hospital Association told Healthcare Dive its member hospitals have been in close contact with New York Blood Center​​, and the organization isn’t aware of any blood supply delays.

Experts highlighted surgical robotics, artificial intelligence and M&A as top trends this year. However, the Trump administration could create challenges for the industry.

Insurers poked holes in the KFF’s methodology — a spokesperson for UnitedHealth called the study “grossly misleading” — to argue that they approve most of the claims they receive.

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug prices in the U.S., Trump has so far been mum on how the controversial law could evolve in the coming years.

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical program to an adjunct approach—for now.